{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:53:27Z","timestamp":1790024007642,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360483"],"award-info":[{"award-number":["82360483"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.116992","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:30:23Z","timestamp":1781627423000},"page":"116992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ISG15 upregulation characterizes a PD-L1-associated immunosuppressive phenotype with CD8+ T-cell dysfunction in hepatocellular carcinoma"],"prefix":"10.1016","volume":"185","author":[{"given":"Chao","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116992_bb0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.intimp.2026.116992_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.intimp.2026.116992_bb0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116992_bb0020","first-page":"172","article-title":"Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a Nationwide analysis of two decades","volume":"12","author":"Abboud","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116992_bb0025","doi-asserted-by":"crossref","first-page":"302","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines insights: hepatobiliary cancers, version 2.2019","volume":"17","author":"Benson","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network\u202f: JNCCN"},{"key":"10.1016\/j.intimp.2026.116992_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"470","author":"Zongyi","year":"2020","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.intimp.2026.116992_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116992_bb0040","article-title":"Integrating quality of life and survival in systemic therapy for advanced hepatocellular carcinoma: a network Meta-analysis","volume":"0","author":"Ciro","year":"2025","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.intimp.2026.116992_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116992_bb0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.116992_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112144","article-title":"A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced hepatocellular carcinoma","volume":"134","author":"Xiao","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116992_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107161","article-title":"Molecular insight into T cell exhaustion in hepatocellular carcinoma","volume":"203","author":"Zhu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116992_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1611365","article-title":"Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages","volume":"16","author":"Fuster-Anglada","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116992_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030538","article-title":"ISG15 and ISGylation in human diseases","volume":"11","author":"Mirzalieva","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116992_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216080","article-title":"Interferon stimulated gene 15 (ISG15) in cancer: an update","volume":"556","author":"Nguyen","year":"2023","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.intimp.2026.116992_bb0080","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.18632\/oncotarget.2316","article-title":"Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.intimp.2026.116992_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7150\/ijms.39823","article-title":"Upregulation of enzymes involved in ISGylation and ubiquitination in patients with hepatocellular carcinoma","volume":"17","author":"Tong","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116992_bb0090","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Jaeoh","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116992_bb0095","article-title":"CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116992_bb0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41419-025-07772-0","article-title":"Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis","volume":"16","author":"Ye","year":"2025","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.intimp.2026.116992_bb0105","article-title":"ISG15 Enhances the Activity of \u03b3-Glutamate Cysteine Ligase to Suppress Apoptosis in High Fat Diet-Promoted Hepatocellular Carcinoma","volume":"12","author":"Liu","year":"2025","journal-title":"Advanced Science (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.intimp.2026.116992_bb0110","doi-asserted-by":"crossref","unstructured":"Barsch M, Sali\u00e9 H, Schlaak A E, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J. Hepatol., 2022, 77(2): 397\u2013409.","DOI":"10.1016\/j.jhep.2022.02.032"},{"key":"10.1016\/j.intimp.2026.116992_bb0115","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/JHC.S464806","article-title":"LAYN serves as a prognostic biomarker and downregulates tumor-infiltrating CD8(+) T cell function in hepatocellular carcinoma","volume":"11","author":"Xiao","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"8","key":"10.1016\/j.intimp.2026.116992_bb0120","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1111\/cas.15004","article-title":"High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence","volume":"112","author":"Muranushi","year":"2021","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116992_bb0125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep4.1643","article-title":"CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma","volume":"5","author":"Yugawa","year":"2021","journal-title":"Hepatol. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2026.116992_bb0130","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00262-019-02422-9","article-title":"ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression","volume":"68","author":"Burks","year":"2019","journal-title":"Cancer immunology, immunotherapy\u202f: CII"},{"key":"10.1016\/j.intimp.2026.116992_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594775","article-title":"Tumor cell-secreted ISG15 promotes tumor cell migration and immune suppression by inducing the macrophage M2-like phenotype","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116992_bb0140","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/2326-6066.CIR-25-0047","article-title":"Chronic ISG15 exposure accelerates CD8+ T-cell dysfunction while increasing PD-1 blockade sensitivity in Oral squamous cell carcinoma","volume":"13","author":"Chen","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116992_bb0145","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8321","article-title":"Interferon-stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response","volume":"47","author":"Zhao","year":"2022","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2026.116992_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120464","article-title":"ISG15 promotes ERK1 ISGylation, CD8+ T cell activation and suppresses ovarian Cancer progression","volume":"10","author":"Yeung","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2026.116992_bb0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-023-04135-1","article-title":"ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma","volume":"21","author":"Qu","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:40:00Z","timestamp":1784230800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926008386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S1567576926008386"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116992","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ISG15 upregulation characterizes a PD-L1-associated immunosuppressive phenotype with CD8+ T-cell dysfunction in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116992"}}